Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Johnson & Johnson

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/09/2018 | 08:49pm CEST

Levi & Korsinsky announces it has commenced an investigation of Johnson & Johnson (NYSE:JNJ) (“Johnson & Johnson” or the “Company”) concerning possible violations of federal securities laws.

On February 5, 2018, CNBC published an article alleging that “court proceedings could expose potentially damaging documents” related to certain Johnson & Johnson’s talc products. On this news, shares of Johnson & Johnson fell $7.29 per share or over 5%, to close at $130.39 on February 5, 2018. To obtain additional information, go to:

http://www.zlkdocs.com/JNJ-Info-Request-Form-6450

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.


© Business Wire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
05:10pJOHNSON & JOHNSON : Cerenovus receives fda clearance for next generation stent r..
PU
04:51pJOHNSON & JOHNSON : Opioid makers, called ‘drug dealers,’ gave ̷..
AQ
02:03pJOHNSON & JOHNSON : Today's Research Reports on Trending Tickers: Johnson & John..
AC
01:02pJOHNSON & JOHNSON : Janssen to Present New Data in Urothelial, Hematologic and P..
AQ
11:02aJOHNSON & JOHNSON : Dendreon takes Provenge earlier in prostate cancer
AQ
11:01aJ&J discontinuing AD trials of BACE1 inhibitor
AQ
05/19JOHNSON & JOHNSON : Janssen to Present New Data in Urothelial, Haematologic and ..
AQ
05/19JOHNSON & JOHNSON : Janssen pulls plug on Alzheimers candidate
AQ
05/19JOHNSON & JOHNSON : ERLEADA™ Significantly Reduced Risk of Prostate Specif..
PU
05/17Dell Technologies Announces Customer Award Winners
AQ
More news
News from SeekingAlpha
10:00aYOUR DAILY PHARMA SCOOP : Abeona Presents Strong Data, Glaxo Nucala Treatment Be.. 
08:23aStocks, Oil And The Dollar Boosted By Eased U.S./China Trade Tensions; Venezu.. 
08:03aHow To Retire With Best Long-Term Investment 
07:13aViiV Healthcare's HIV med Juluca OK'd in Europe 
06:57aWALL STREET BREAKFAST : U.S.-China Trade War 'On Hold' 
Financials ($)
Sales 2018 81 536 M
EBIT 2018 24 881 M
Net income 2018 16 279 M
Debt 2018 9 501 M
Yield 2018 2,90%
P/E ratio 2018 18,40
P/E ratio 2019 17,08
EV / Sales 2018 4,19x
EV / Sales 2019 3,84x
Capitalization 332 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 145 $
Spread / Average Target 17%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-11.08%332 184
PFIZER-1.41%212 424
NOVARTIS-6.55%202 969
ROCHE HOLDING LTD.-8.90%193 622
MERCK AND COMPANY5.10%158 916
AMGEN1.38%115 567